Modulation of animal cellular responses with compositions containing isoxanthopterin-8-(1'-.beta.-aldoglycosidyl) derivatives

A method of enhancing cellular immune responses of leucocytes comprising the steps of:

• contacting leucocytes with a composition containing a diluent amount of a physiologically tolerable carrier admixed with an immune response-modulating effective amount of an active ingredient that is an isoxanthopterin derivative whose structure conforms to that of the formula ##STR10## wherein R.sub.1 is a radical selected from the group consisting of hydrogen, lower alkyl, hydroxy lower alkyl, polyhydroxy lower alkyl, phenyl, phenyl-lower alkyl, lower alkyl phenyl, lower alkoxy phenyl, halophenyl, trifluoromethyl phenyl, hydroxy, oxo, lower alkoxy, phenyl-lower alkoxy, halo, mercapto, thioxo, lower alkylthio, lower alkyloylthio, phenyl-lower alkylthio, lower alkanoyl, carboxy, lower alkoxy carbonyl, lower alkylcarboxy, lower alkylene lower alkylcarboxylate, lower alkoxy lower alkyl carbonyl, and carboxamido and lower alkyl carboxamido in which the carboxamido group has the formula CONR.sub.3 R.sub.4 wherein R.sub.3 and R.sub.4 are the same or different and are selected from the group consisting of hydrogen and lower alkyl or NR.sub.3 R.sub.4 together form a heterocyclic ring having five or six atoms in the ring;
• R.sub.2 is a beta-bonded aldoglycoside radical selected from the group consisting of 1'-aldopentosidyl, 1'-aldohexosidyl, mono-deoxygenated 1'-aldopentosidyl, and mono-deoxygenated 1'-aldohexosidyl and their O-substituted lower alkyl, lower alkanoyl, benzyl and benzoyl derivatives wherein an O-substituent, if present on one oxygen, is present on all available ring substituent oxygens;
• the tautomers of said isoxanthopterin derivative;
• and
• the pharmaceutically acceptable salts of said isoxanthopterin derivative;
• and
• maintaining said contact for a time period sufficient for said leucocytes to modulate their immune responses.

A method of enhancing the secretion of antibodies to a preselected immunogen comprising the steps of:

• contacting immunoglobulin-producing cells with a composition containing a diluent amount of a physiologically tolerable carrier admixed with (a) an effective amount of a preselected immunogen to induce secretion of said antibodies and (b) an adjuvant amount of a isoxanthopterin derivative whose structure conforms to that of the formula ##STR12## wherein R.sub.1 is a radical selected from the group consisting of hydrogen, lower alkyl, hydroxy lower alkyl, polyhydroxy lower alkyl, phenyl, phenyl-lower alkyl, lower alkyl phenyl, lower alkoxy phenyl, halophenyl, trifluoromethyl phenyl, hydroxy, oxo, lower alkoxy, phenyl-lower alkoxy, halo, mercapto, thioxo, lower alkylthio, lower alkyloylthio, phenyl-lower alkylthio, lower alkanoyl, carboxy, lower alkoxy carbonyl, lower alkylcarboxy, lower alkylene lower alkylcarboxylate, lower alkoxy lower alkyl carbonyl, and carboxamido and lower alkyl carboxamido in which the carboxamido group has the formula CONR.sub.3 R.sub.4 wherein R.sub.3 and R.sub.4 are the same or different and are selected from the group consisting of hydrogen and lower alkyl or NR.sub.3 R.sub.4 together form a heterocyclic ring having five or six atoms in the ring;
• R.sub.2 is a beta-bonded aldoglycoside radical selected from the group consisting of 1'-aldopentosidyl, 1'-aldohexosidyl, mono- deoxygenated 1'-aldopentosidyl, and mono-deoxygenated 1'-aldohexosidyl and their O-substituted lower alkyl, lower alkanoyl, benzyl and benzoyl derivatives wherein an O-substituent, if present on one oxygen, is present on all available ring substituent oxygens;
• the tautomers of said isoxanthopterin derivative;
• and
• the pharmaceutically acceptable salts of said isoxanthopterin derivative;
• and
• maintaining said contact for a time period sufficient for said contacted cells to secrete antibodies to said immunogen.